# Editorial: Molecular mechanisms underlying pain relief and drug tolerance

Quirin Krabichler, Ana Reynders

<figure><img src="image_1.png" /></figure>

► To cite this version:

Quirin Krabichler, Ana Reynders. Editorial: Molecular mechanisms underlying pain relief and drug tolerance. Frontiers in Molecular Neuroscience, 2023, 16, 10.3389/fnmol.2023.1214264. hal-04254183

HAL Id: hal-04254183

https://amu.hal.science/hal-04254183v1

Submitted on 23 Oct 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
<figure><img src="image_3.png" /></figure>

Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY
Robert John Vandenberg,
The University of Sydney, Australia

*CORRESPONDENCE

Quirin Krabichler

✉ quirin.krabichler@zi-mannheim.de

Ana Reynders

✉ ana.reynders@univ-amu.fr

RECEIVED 29 April 2023

ACCEPTED 04 May 2023

PUBLISHED 22 May 2023

CITATION

Krabichler Q and Reynders A (2023) Editorial: Molecular mechanisms underlying pain relief and drug tolerance.

Front. Mol. Neurosci. 16:1214264.

doi: 10.3389/fnmol.2023.1214264

COPYRIGHT

© 2023 Krabichler and Reynders. This is an open-access article distributed under the terms of the [Creative Commons Attribution License (CC BY)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Editorial: Molecular mechanisms underlying pain relief and drug tolerance

Quirin Krabichler¹* and Ana Reynders²*

¹Department of Neuropeptide Research in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, ²Aix-Marseille-Université, CNRS, Institut de Biologie du Développement de Marseille, Marseille, France

KEYWORDS

pain, analgesia, planarians, morphine, oxytocin

## Editorial on the Research Topic

### Molecular mechanisms underlying pain relief and drug tolerance

Nociception is the process by which the nervous system detects and responds to noxious stimuli. Reaching brain and cortical areas, the nociceptive message might give rise to the sensation of pain. Noxious stimuli are detected by “nociceptors,” specialized primary afferent sensory neurons, which express various types of receptors and ion channels. Upon their activation, they release neurotransmitters which transmit pain signals to the spinal cord and the brain. There, these signals are processed and interpreted, leading to the perception of pain.

Pain is a highly averse sensation. It is present in different forms across the animal kingdom, although the quality of the sensation is thought to vary depending on the complexity of the animal's nervous system. Nevertheless, the basic neural and molecular mechanisms are homologous across the phylogenetic tree of animals. It is therefore both important and fruitful to study these mechanisms from the angle of comparative neurobiology—even more so, since much is still to be learned, for the sake of pure scientific curiosity, but especially for the sake of finding new cures. One of the major challenges in treating pain and especially chronic pain is that the use of established painkillers, such as opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and local anesthetics, can lead to the development of tolerance, where the body becomes less responsive to the effects of the drug over time. This is thought to occur due to changes in the molecular mechanisms underlying nociception, such as increased expression of opioid receptors or desensitization of ion channels. As a result, higher doses of the drug are required to achieve the same level of pain relief, which can increase the risk of side effects and addiction.

New ways to treat pain will require improved understanding of the underlying mechanisms. Many molecular mechanisms of nociception have been known for decades, but amazingly, new ones continue to be discovered all the time. Many interesting novel findings relate to endogenous analgesic molecules released by various groups of neurons in the brain, which can inhibit pain transmission and provide pain relief. For example, Oxytocin (OT) has emerged as an intriguing new pain-killer molecule. Indeed, in addition to its well-established roles in mammalian reproduction and social interactions, this neuropeptide synthetized in the hypothalamus is increasingly acknowledged for its ability to regulate nociception at peripheral, spinal and supra-spinal sites. Accordingly, endogenous OT released following peripheral inflammation suppresses nociception and promotes analgesia.
Moreover, exogenously administrated OT alleviates inflammatory
and neuropathic pain. Apart from endogenous analgesics, many
fascinating new discoveries are also still made with respect to
classical and long-established painkillers such as opioids.

In this Frontiers in Molecular Neuroscience Research Topic
“Molecular mechanisms underlying pain relief and drug tolerance,”
five recent research articles are presented, which address a variety
of current topics in pain research.

The study by Sun et al. focused on the analgesic actions
of OT in the spinal cord. While the consensual view on the
mechanisms underlying OT-mediated anti-nociception rely on
the activation of oxytocin receptors (OTR) and the subsequent
enhancement of inhibition of nociceptive inputs, this study
provides a new mechanistic insight. Using a model of neuropathic
pain, the authors propose that OT alleviates pain by promoting
spinal GABA release and dampening presynaptic TRPV1-mediated
neurotransmission. Electrophysiological recordings on acute spinal
cord slices demonstrates that OT concomitantly increased the
frequency and the amplitude of spontaneous GABAergic currents,
while decreasing capsaicin-evoked EPSC. Importantly, this action
was completely blocked by application of metabotropic GABA<sub>B</sub>
receptor antagonist, revealing an interaction of OT with spinal
TRPV1-GABA<sub>B</sub> system. Behavioral analysis of OT-injected naïve
and neuropathic rats demonstrates the anti-nociceptive and
analgesic properties of OT. Consistent with the electrophysiological
results, OT normalized the up-regulation of TRPV1 induced by
neuropathic lesion and had no effect when administrated to TRPV1
knock-out animals.

As further discussed by Gonzalez-Hernandez and Charlet in
their commentary on the paper by Sun et al., these findings are
consistent with another original study reporting a direct interaction
of OT with TRPV1 *in vitro*, in heterologous cellular system and
*in sillico*, in planar lipid bilayers. In this commentary, the authors
summarize the knowledge on the mechanisms underlying OT-
mediated anti-nociception and further underscore that the findings
by Sun et al. illustrate a more complex than anticipated mode-of-
action, in which several receptors, other than the classical OTR
and various cellular targets, in addition to neurons may come
into play.

These papers underscore the growing need to discover pain-
relieving molecules. Indeed, one of the most widely used analgesic
drug for the treatment of several pain conditions including
inflammatory and neuropathic pain, is morphine. However, as
illustrated by the recent opioid crisis in the United States, the
use and efficiency of morphine is limited by side effects ranging
from analgesic tolerance to life-threatening respiratory depression.
Morphine tolerance arises following repeated drug administration
and escalating doses are required to obtain the same analgesic effect.
Despite advances in the elucidation of the mechanisms responsible
for morphine tolerance, which include receptor internalization and
de-sensitization, there are currently no therapeutic strategies to
counteract this effect. In this context, Liu et al. examined the
relevance of morphine-induced endoplasmic reticulum (ER) stress
as a potential therapeutic target for morphine tolerance. They
show that repetitive administration of morphine in rats induces
tolerance, which in turns triggers the up-regulation of several ER
stress sensor proteins and associated signaling pathways, including
IRE1 and ATF6, in the spinal cord. Consistently, local inhibition of

these pathways significantly attenuate morphine tolerance *in vivo*,
providing a possible therapeutic basis.

Along the same line, Gabel et al., in their review of
literature, discuss how morphine metabolism impacts on the
efficiency of morphine analgesia. In particular, they focus on
morphine-3-glucoronide (M3G), one of the main morphine-
derived metabolites, which has been suggested to exhibit pro-
nociceptive activity, thereby counter-acting morphine effect. Based
on animal studies, the authors highlight several mechanisms likely
to account for M3G pro-nociceptive action, including binding
to morphine receptor and mobilization of the toll-like receptor
4 pathway. While these studies have a potential to increase the
knowledge on the mechanisms underlying morphine side-effects,
M3G effects in human patients appear less robust than those
observed in rodents.

Finally, Reho et al. argue on the use of planarians as an
original model system for the analysis of nociceptive behavior.
Planarians are invertebrate “flatworms,” mostly studied in the field
of regenerative medicine but also in drug abuse paradigms. More
recent studies have provided evidence supporting the existence of a
nociceptive system in planarians and of a subsequent nociceptive
behavior. However, up-to-date, there is no consensus on how
to experimentally measure such a behavior. In their review, the
authors provide an exhaustive list of the known pharmacological
compounds and their effect on planarians behavior. They further
enumerate most of the terms used in dedicated studies, to
describe planarians behavior. Overall, this review stands as a
resource containing important information for the accurate use of
planarians as a model system in the pain field.

Author contributions

QK and AR wrote the editorial topic. All authors contributed to
the article and approved the submitted version.

Acknowledgments

We would like to thank Dr. Alexandre Charlet and Prof.
Valery Grinevich for their guidance and their comments on this
editorial topic.

Conflict of interest

The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the
authors and do not necessarily represent those of their affiliated
organizations, or those of the publisher, the editors and the
reviewers. Any product that may be evaluated in this article, or
claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.